Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 453,251 shares of the company’s stock after acquiring an additional 14,372 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Teva Pharmaceutical Industries were worth $8,168,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TEVA. UMB Bank n.a. lifted its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the period. Smithfield Trust Co raised its stake in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares in the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $52,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries during the third quarter valued at about $52,000. Finally, GAMMA Investing LLC boosted its stake in Teva Pharmaceutical Industries by 105.7% during the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after buying an additional 1,741 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.78 on Monday. The company has a market capitalization of $19.01 billion, a price-to-earnings ratio of -19.74, a P/E/G ratio of 1.30 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The stock’s fifty day simple moving average is $17.56 and its 200-day simple moving average is $17.35.

Insider Activity

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TEVA shares. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.